Health News from Medical News Today: Signal Genetics Announces Commercialization Partnership With NeoGenomics Laboratories For Multiple Myeloma Gene Expression Test

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Signal Genetics Announces Commercialization Partnership With NeoGenomics Laboratories For Multiple Myeloma Gene Expression Test 31 May 2011, 8:00 am Signal Genetics, the parent company of Myeloma Health LLC and Respira Health LLC, a privately held predictive genetic testing company focused on oncology, announced a new agreement under which NeoGenomics Laboratories will offer Signal Genetics' new gene expression profile test for Multiple Myeloma (MyPRS™) to pathologists and hospital-based hematologists/oncologists nationwide. Myeloma Prognostic Risk Signature™ (MyPRS) offers the most detailed expression profiling information for multiple myeloma patients available on the market... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.